Clinical Trial Search

Primary: Biochemical Disease Free Survival: Estimated Percentage of Participants With Biochemical Disease-free Survival at 5 Years — 90; 81 percentage of patients — p=0.01

Primary: Geometric Mean Titers of Influenza Antibodies Before and After Vaccination With a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route — 142; 116…

Primary: Number of Doses of Fentanyl Administered in the Postoperative Period Prior to Discharge. — 1.5; 1.7 fentanyl doses

Primary: Percentage of Participants Achieving the Combined Response at the End of the Follow-up Period — 11.8; 25.0; 20.0 percentage of participants — p=0.08

Primary: Change From Baseline in Pain Intensity at Days 14-18 — -40.4; -34.9 Units on a scale

Primary: Percent Changes From Baseline in Total Lesion Counts — 68.6; 82.7; 81.6 percent change

Primary: Percentage of Participants With Serum Urate <5.0 mg/dL at Month 3 — 0.3; 15.7; 25.9; 42.6 percentage of participants — p=<0.001

Primary: Infection Rate — 31.4; 36.5 percentage of participants

Primary: Number of Participants With Any Adverse Events and Any Serious Adverse Events — 7; 0 participants

Primary: Mean Change From Baseline in Short Inflammatory Bowel Disease Questionnaire (SIBDQ): Total Score — 17.4 units on a scale — p=<0.001

Primary: Percent of Patients Achieving Stable Disease (SD) — 48.8 % participants

Primary: Percentage of Participants in Each Treatment Arm in Cohort 2 With HIV-1 RNA < 50 Copies/mL at Week 24 — 96.6; 91.3 percentage of participants — p=0.23

Primary: Percentage of Participants With Hemoglobin (Hb) Response — 94.12; 93.51 percentage of participants — p=<0.0001

Primary: Remission After 8-week of Treatment — 17; 14 Participants — p=0.526

Primary: Percentage of Participants Achieving <40 Copies/mL Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) at Week 48 — 88.9; 88.3 Percentage of participants